| Revenue growth | Highest Q1 revenue; Consolidated revenue grew 2.3% YoY. |
|---|---|
| Margins | EBITDA margin at 16.7%; PAT margin at 11.1%. |
| Demand visibility | Strong uptake in chronic therapies and U.S. respiratory market. |
Growth
One India revenue grew 12% YoY to INR 3,452 Cr. North America recorded $162 Mn revenue.
Outlook
Focus on chronic therapy expansion in India and ramping up gVentolin supply in the U.S. market.
Risks
EBITDA and PAT margins saw a YoY contraction from 25.6% to 16.7% and 18.7% to 11.1% respectively.
Last quarter's promises, checked
Delivered
- Guided 17 new launches in Trade Generics → Launched gVentolin, Yurpeak, and others (= BEAT)
- Guided India chronic mix at 60% → Delivered 60.4% (= BEAT)
- Guided US gVentolin launch in Q1 → Delivered Q1 launch (= BEAT)
Partly delivered
- Guided double-digit India growth → Delivered 12% (= PARTIAL)
Missed
- Guided FY27 EBITDA margin 18.5%-20% → Delivered 16.7% in Q1 (= MISS)
- Guided US revenue run-rate improvement → Delivered $162M vs $155M prev. quarter (= MISS)
Investor Presentation filed with BSE, NSE: CIPLA. Summary written with AI assistance from the document.
Cipla Ltd: key numbers
- Share price
- ₹1,399.70
- Market cap
- ₹1,13,076 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 33.5×Sector 50.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Employee Stock Options
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Management Change
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
Cipla Other Announcement
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
Cipla Acquisition
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
Cipla Earnings Call Transcript: Key Takeaways
Cipla delivered record Q1 FY27 revenue of INR 7,119 Cr with 2% reported growth (4% adjusted). Strategy focuses on U.S. respiratory launches and 'One India' chronic therapies.
Cipla Q1 FY27 Results: Net Profit ₹785.5 Cr, Down 39.2% YoY
Cipla Ltd reported revenue from operations of ₹7,119 Cr (+2.3% YoY) and net profit of ₹785.5 Cr (-39.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹785.5 Cr · -39.2% YoY